The CM cases in our cohort also harbored mutations in c-KIT, PTEN, and BAP1. These findings of mutations in c-KIT, NRAS, and PTEN are congruent with other literature [1,6], with c-KIT mutations reported in 39% of mucosal melanoma and being feasible for targeted therapy [42]. This evidence concerns the gene KIT and cutaneous mastocytosis.